SEC Comment Letter 0000000000-24-013819 to Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc.
Date: Dec. 16, 2024 · CIK: 0001419041 · Accession: 0000000000-24-013819
AI Filing Summary & Sentiment
File numbers found in text: 333-283814
Letter
December 16, 2024 Paul A. Wagner, Ph.D. Chief Executive Officer Forte Biosciences, Inc. 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 Re:Forte Biosciences, Inc. Registration Statement on Form S-3 Filed December 13, 2024 File No. 333-283814 Dear Paul A. Wagner Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Dan Koeppen, Esq.
Show Raw Text
December 16, 2024
Paul A. Wagner, Ph.D.
Chief Executive Officer
Forte Biosciences, Inc.
3060 Pegasus Park Drive, Building 6
Dallas, Texas 75247
Re:Forte Biosciences, Inc.
Registration Statement on Form S-3
Filed December 13, 2024
File No. 333-283814
Dear Paul A. Wagner Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Dan Koeppen, Esq.